DOJ Backs AbbVie in 340B Drug Pricing Dispute: What’s at Stake?
The U.S. Department of Justice (DOJ) is siding with pharmaceutical giant AbbVie in a lawsuit against the state of Colorado, escalating a critical battle over the 340B Drug Pricing Program. This marks the first time the federal government has weighed in on the numerous manufacturer lawsuits challenging state laws related to the program, signaling a potentially significant shift in how these disputes are resolved.
Understanding the 340B Program
Established over 30 years ago, the 340B program was created to help hospitals and clinics provide affordable care to low-income and rural patients. Participating entities – hospitals, clinics, and other healthcare providers – receive discounted prices on outpatient drugs, allowing them to stretch their budgets and serve vulnerable populations. Drug manufacturers participate in the program as a condition of being able to sell their medications to Medicare and Medicaid.
The Contract Pharmacy Controversy
For years, the 340B program operated with relative stability. However, around six years ago, many drug manufacturers began restricting discounts when drugs were dispensed through contract pharmacies. These pharmacies, used by hospitals and clinics to provide convenient access for patients, allow patients to fill prescriptions at local retailers.
Drug companies claim that the use of contract pharmacies has led to abuses, including duplicate billings, product diversion, and improper rebates. They argue that the program’s original intent was for drugs to be dispensed directly to patients at covered entity facilities.
Colorado’s Law and the DOJ’s Position
Colorado enacted a law – the 340B Contract Pharmacy Protection Act – specifically prohibiting drug manufacturers from placing restrictions on discounts to pharmacies. AbbVie sued, arguing that the state law violates federal law. The DOJ, in an amicus brief, supports AbbVie’s position, asserting that federal law preempts Colorado’s statute. The DOJ argues that the smooth functioning of the 340B program is a federal interest.
Implications for the Future of 340B
The DOJ’s involvement has broad implications. It suggests the federal government may be inclined to side with manufacturers in disputes over contract pharmacy arrangements. This could embolden other drugmakers to pursue similar legal challenges against states with laws protecting 340B discounts. A ruling in favor of AbbVie could significantly limit the ability of hospitals and clinics to utilize contract pharmacies, potentially reducing access to affordable medications for patients.
The case also highlights the ongoing tension between drug manufacturers and the healthcare providers who rely on 340B savings. The program’s future hinges on finding a balance between preventing abuse and ensuring that vulnerable patients continue to have access to affordable care.
Recent Legal Developments
In September 2025, an appeals court upheld a lower court’s denial of AbbVie’s preliminary injunction, preserving Mississippi’s 340B contract pharmacy law. This ruling demonstrates that legal battles surrounding the program are complex and outcomes are not always predictable.
Frequently Asked Questions
What is the 340B program? The 340B Drug Pricing Program is a federal program that provides discounted drugs to eligible healthcare organizations.
Why are drug manufacturers restricting discounts? Drug manufacturers allege that contract pharmacies lead to abuses like duplicate billing and product diversion.
What is Colorado’s law trying to do? Colorado’s law aims to protect 340B discounts when drugs are dispensed through contract pharmacies.
What does the DOJ’s involvement mean? The DOJ’s support of AbbVie suggests the federal government may favor manufacturers in disputes over the program.
Did you know? The 340B program has been a subject of debate and legal challenges for several years, with ongoing efforts to refine its rules and address concerns about program integrity.
Pro Tip: Stay informed about legislative updates and court decisions related to the 340B program to understand how it may impact your organization or patients.
Want to learn more about the 340B program and its impact on healthcare? Subscribe to STAT+ for in-depth analysis and exclusive reporting.
